Department of Oncology-Pathology
The Department of Oncology-Pathology conducts basic, translational and clinical research and educational activities related to cancer.
Lars Holmgren on twitter
Follow the chair of the department of Oncology-Pathology Lars Holmgren on twitter.
Patients with melanoma and diabetes benefit from metformin treatment
Isabelle Krakowski and Hanna Eriksson with colleagues have published an article in the British Journal of Dermatology (selected as Editor’s Choice) where they show that treatment with metformin (a drug for treatment of diabetes) improves the overall survival in patients with cutaneous melanoma and diabetes compared to no metformin treatment. These results are clinically relevant considering the expected future increase of melanoma patients with diabetes, suggesting that metformin is a suitable anti-diabetic therapy for this patient group.
Major EU funding for development of AI in healthcare
Päivi Östling, together with researchers from Centre for Imaging Research (CIR), SciLifeLab and RISE have received a grant of over 100 million SEK from the European Commission's Digital Europe programme. The project, called TEF-Health, will, among other things, promote the rapid introduction of new artificial intelligence (AI) and robotics solutions in healthcare.
Hildur Helgadottir receives large EU-grant
Hildur Helgadottir at OnkPat is receiving an EU-grant of approximately 3.5 million SEK from HORIZON Europe. The total grant is nearly 90 million SEK and the project is called “Novel health care strategies for melanoma in children, adolescents and young adults”. The grant is awarded for four years and Hildurs group at Karolinska Institutet is the only one in Sweden participating in this international collaboration.
33 million SEK to OnPat researchers from Radiumhemmets Forskningsfonder
In this year's announcement of project grants from Radiumhemmets Forskningsfonder, OnkPat received a total of 33 million SEK. 32 researchers were granted funding. The largest grant was 3 million SEK received by professor Anders Österborg.
Double embryo transfer in assisted reproduction increased the risk of complications in singleton births
The risk of complications in assisted reproduction is higher when two embryos are transferred, instead of one embryo. This has been shown in a study published by professor Kenny Rodriguez-Wallberg and Frida Lundberg in the journal JAMA Pediatrics, which included all births in Sweden 2007-2017.
Identification of breast cancer patients with poor survival who may benefit from alternative treatment
Alexios Matikas, Theodoros Foukakis and colleagues have published an article from the Swedish randomized trial PREDIX HER2 in Clinical Cancer Research. They show that early response to preoperative treatment according to PET/CT predicts long-term survival. In addition, combined assessment of on-treatment PET/CT and baseline tumor infiltrating lymphocytes (TILs) counted by using machine learning-based image analysis identifies patients with poor response to treatment and worse survival. These results suggest that early identification of poor responders by using PET/CT and digital TILs may facilitate adaptation of the preoperative strategy.
Potential new treatment for tumors with nonsense mutant TP53
Mireia Palomar-Siles, Angelos Heldin and Klas Wiman with colleagues have published an article in Cell Death & Disease which shows that 5-Fluorouridine can induce full-length funtional p53 protein in cancer cells with nonsense mutation in TP53, the gene encoding p53. The induction of full-length p53 triggers cancer cell death. These results suggest that 5-Fluorouridine should be explored as potential therapeutic agent for tumors with nonsense mutant TP53.
SAVE THE DATE
16-17th of May 2023: 6th Cancer Swedish Research Meeting
The meeting is open to all clinical, preclinical researchers and others with an interest in cancer research from the organizing universities.
Venue: Karolinska Institutet, Aula Medica, Erling Persson-salen, Nobels väg 6, 171 65 Solna
Host: Cancer Research KI
Organizers: U-CAN from Uppsala/Umeå Universities, LUCC (Lund University Cancer Centre), University of Gothenburg, and Cancer Research KI from Karolinska Institutet.